« Return to News | Clinical Intelligence

DepoMed Sees Negative Results from Controlled-Release Gabapentin

Monday, July 16, 2007 02:31 PM

DepoMed reported negative results from a phase III trial of Gabapentin GR for the treatment of postherpetic neuralgia (PHN). The product is a twice-daily, controlled-release tablet formulation of the anticonvulsant and analgesic gabapentin.

This randomized, double-blind, placebo-controlled trial enrolled 407 subjects who were placed into one of three treatment groups to receive Gabapentin GR once daily, Gabapentin GR twice daily (each 1800 mg/day) or placebo for 10 weeks.

The primary endpoint was the reduction in average daily pain scores from baseline to endpoint with Gabapentin GR compared to placebo. Statistical significance was not reached for either active treatment group. The average daily reductions were 1.83 (once daily), 1.72 (twice daily) and 1.43 (placebo). However, statistical significance was achieved in all the secondary endpoints, including Clinical Global Impression of Change (p less than 0.001) and Patient Global Impression of Change (p=0.009).

DepoMed plans to fully evaluate the data in order to determine a future course of action.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.